文献速递中药与中成药合理使用

南非醉茄与AYUSH-64对CYP-450酶及瑞德西韦相互作用体外研究

In vitro effect of Withania somnifera, AYUSH-64, and remdesivir on the activity of CYP-450 enzymes: Implications for possible herb-drug interactions in the management of COVID-19.
PubMed 文献 · Front Pharmacol · 2022-10-12

本研究探讨阿育吠陀药物南非醉茄(ashwagandha)和AYUSH-64对CYP3A4、CYP2C8和CYP2D6的体外影响,并评估与瑞德西韦的潜在草药-药物相互作用。人肝微粒体实验显示瑞德西韦对三种酶有中度抑制,南非醉茄单用或联用均无抑制,AYUSH-64对CYP2C8有中度抑制。提示南非醉茄与CYP3A4/2C8/2D6底物合用较安全,而AYUSH-64与CYP2C8底物合用需谨慎。

要点

  • 南非醉茄单用或与瑞德西韦联用对CYP3A4、CYP2C8、CYP2D6均无抑制作用。
  • AYUSH-64对CYP2C8有中度抑制作用,与CYP2C8底物联用需谨慎。
  • 瑞德西韦对CYP3A4、CYP2C8、CYP2D6有中度抑制作用。

核心结论

  • 南非醉茄与CYP3A4、CYP2C8、CYP2D6底物合用似乎安全。
  • AYUSH-64与CYP2C8底物药物联用需谨慎。

研究设计与样本

  • 体外研究:用LC-MS/MS表征南非醉茄和AYUSH-64水提物,并行计算机模拟和人肝微粒体CYP-450抑制实验。

主要发现

  • 从南非醉茄和AYUSH-64提取物中分别初步鉴定出11和24种植物化学成分。
  • 计算机模拟显示多数成分ADME性质良好,部分可能抑制CYP-450。
  • 人肝微粒体实验显示瑞德西韦对CYP3A4、2C8、2D6有中度抑制。
  • 南非醉茄单用或与瑞德西韦联用对CYP3A4、2C8、2D6无抑制。
  • AYUSH-64趋势类似,但对CYP2C8有中度抑制。

临床怎么用

  • 南非醉茄可与CYP3A4、CYP2C8、CYP2D6底物合用,但仍需注意监测。
  • AYUSH-64与CYP2C8底物药物联用时应谨慎,避免潜在相互作用。

局限性

  • 本研究为体外实验,需进一步开展临床前和临床药代动力学研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ayurvedic medicines Withania somnifera Dunal (ashwagandha) and AYUSH-64 have been used for the prevention and management of COVID-19 in India. The present study explores the effect of Ashwagandha and AYUSH-64 on important human CYP enzymes (CYP3A4, CYP2C8, and CYP2D6) to assess their interaction with remdesivir, a drug used for COVID-19 management during the second wave. The study also implies possible herb-drug interactions as ashwagandha and AYUSH-64 are being used for managing various pathological conditions. Aqueous extracts of ashwagandha and AYUSH-64 were characterized using LC-MS/MS. A total of 11 and 24 phytoconstituents were identified putatively from ashwagandha and AYUSH-64 extracts, respectively. In addition, in silico studies revealed good ADME properties of most of the phytoconstituents of these herbal drugs and suggested that some of these might possess CYP-450 inhibitory activity. In vitro CYP-450 studies with human liver microsomes showed moderate inhibition of CYP3A4, 2C8, and 2D6 by remdesivir, while ashwagandha had no inhibitory effect alone or in combination with remdesivir. AYUSH-64 also exhibited a similar trend; however, a moderate inhibitory effect on CYP2C8 was noticed. Thus, ashwagandha seems to be safe to co-administer with the substrates of CYP3A4, CYP2C8, and CYP2D6. However, caution is warranted in prescribing AYUSH-64 along with CYP2C8 substrate drugs. Furthermore, preclinical and clinical PK studies would be helpful for their effective and safer use in the management of various ailments along with other drugs.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Kasarla SS, Borse SP, Kumar Y, et al. In vitro effect of Withania somnifera, AYUSH-64, and remdesivir on the activity of CYP-450 enzymes: Implications for possible herb-drug interactions in the management of COVID-19. Front Pharmacol. 2022. PMID: 36313313. doi:10.3389/fphar.2022.973768

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。